U.S. Markets
Regeneron Pharmaceuticals Inc. (REGN) Q3 2026 (USD) Adj. EPS 20.07 (exp. 16.19), Revenue 5.1bln (exp. 4.56bln); Sees FY outlook for capex of USD 1.05 - 1.1bln
ORIGINAL · NewsquawkRegeneron Pharmaceuticals Inc. (REGN) Q3 2026 (USD) Adj. EPS 20.07 (exp. 16.19), Revenue 5.1bln (exp. 4.56bln); Sees FY outlook for capex of USD 1.05 - 1.1blnRead originalHide original
Dupixent global net sales (recorded by Sanofi) increased 35% to USD 6.5bln. EYLEA HD U.S. net sales increased 62% to USD 699mln. Libtayo global net sales increased 51% to USD 550mln.
StockNow breaking-news AI analysis
The October 30 headline reports Regeneron Q3 adjusted EPS and revenue above expectations and gives a full-year capital-expenditure outlook of $1.05–$1.1 billion.
News detail
Dupixent global net sales (recorded by Sanofi) increased 35% to USD 6.5bln. EYLEA HD U.S. net sales increased 62% to USD 699mln. Libtayo global net sales increased 51% to USD 550mln.
Related stocks
2 stocks
What do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.